Lynn Seely Sells 7,455 Shares of Lyell Immunopharma (NASDAQ:LYEL) Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) CEO Lynn Seely sold 7,455 shares of the firm’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $23.39, for a total value of $174,372.45. Following the transaction, the chief executive officer owned 74,266 shares of the company’s stock, valued at $1,737,081.74. This trade represents a 9.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Lynn Seely also recently made the following trade(s):

• On Tuesday, February 10th, Lynn Seely sold 438 shares of Lyell Immunopharma stock. The shares were sold at an average price of $23.12, for a total transaction of $10,126.56.

Lyell Immunopharma Stock Performance

Shares of NASDAQ LYEL opened at $25.84 on Friday. Lyell Immunopharma, Inc. has a 52-week low of $7.65 and a 52-week high of $45.00. The company’s 50 day moving average price is $27.99 and its 200-day moving average price is $19.73. The company has a market capitalization of $548.84 million, a P/E ratio of -1.12 and a beta of -0.14.

Lyell Immunopharma (NASDAQ:LYEL) last released its earnings results on Wednesday, November 12th. The company reported ($2.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.81) by $0.68. Lyell Immunopharma had a negative net margin of 794,292.69% and a negative return on equity of 96.68%. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.01 million. Analysts forecast that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Thursday, January 22nd. HC Wainwright raised shares of Lyell Immunopharma from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $20.00 to $45.00 in a research report on Tuesday, December 9th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $45.00.

Key Lyell Immunopharma News

Here are the key news stories impacting Lyell Immunopharma this week:

• Positive Sentiment: Lyell announced dosing of the first patient in PiNACLE, a first‑of‑its‑kind randomized Phase 3 head‑to‑head CAR‑T trial (rondecabtagene autoleucel vs. liso‑cel/axi‑cel) in 2L relapsed/refractory large B‑cell lymphoma — a meaningful clinical/regulatory milestone that can materially de‑risk the program and support future value if enrollment and early readouts progress. PiNACLE Phase 3 dosing
• Neutral Sentiment: Analyst and institutional positioning are mixed: HC Wainwright has previously upgraded LYEL (lifting its target), and institutional ownership is high (~66%), which can amplify moves but doesn’t change near‑term binary clinical risk. MarketBeat LYEL profile
• Neutral Sentiment: General oncology coverage (e.g., exercise recommendations for older cancer survivors) is unlikely to move LYEL shares directly; it’s background sector news rather than company‑specific. Exercise Recs for Older Cancer Survivors
• Negative Sentiment: Clustered insider selling: CEO Lynn Seely, COO Stephen Hill, Gary K. Lee and other insiders reported multiple sales on Feb. 10–11 that meaningfully reduced their positions. Such clustered disposals can weigh on near‑term sentiment even if for diversification or tax reasons. SEC filings are available. CEO 2/11 Form 4

Institutional Trading of Lyell Immunopharma

Several hedge funds have recently bought and sold shares of LYEL. BBR Partners LLC acquired a new position in Lyell Immunopharma during the fourth quarter worth $210,000. Marshall Wace LLP bought a new stake in shares of Lyell Immunopharma during the second quarter worth about $94,000. Jane Street Group LLC acquired a new stake in shares of Lyell Immunopharma in the 4th quarter worth about $382,000. Bridgeway Capital Management LLC bought a new position in Lyell Immunopharma in the 2nd quarter valued at about $159,000. Finally, Clarius Group LLC boosted its stake in Lyell Immunopharma by 4.3% during the 3rd quarter. Clarius Group LLC now owns 19,958 shares of the company’s stock valued at $324,000 after purchasing an additional 820 shares during the last quarter. Institutional investors and hedge funds own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.